Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Oncotelic Therapeutics, Inc. (OTLC) had Return on Tangible Equity of -101.92% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-4.52M |
|
-- |
|
-- |
|
$3.58M |
|
$-3.58M |
|
$-1.20M |
|
$-4.78M |
|
$-4.78M |
|
$-4.78M |
|
$-4.78M |
|
$-4.78M |
|
$-4.78M |
|
$-3.58M |
|
$-0.25M |
|
404.40M |
|
404.40M |
|
$-0.01 |
|
$-0.01 |
|
| Balance Sheet Financials | |
$0.13M |
|
-- |
|
$26.54M |
|
$26.68M |
|
$19.20M |
|
-- |
|
-- |
|
$19.20M |
|
$7.48M |
|
$4.69M |
|
$7.48M |
|
407.29M |
|
| Cash Flow Statement Financials | |
$-0.74M |
|
-- |
|
$0.66M |
|
$0.19M |
|
$0.11M |
|
$-0.08M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.01 |
|
-- |
|
-- |
|
-- |
|
1.75 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.74M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-63.92% |
|
|
Return on Tangible Equity |
-101.92% |
-17.92% |
|
-63.92% |
|
$0.02 |
|
$-0.00 |
|
$-0.00 |
|